Date: 2015-04-27
Type of information: Distribution agreement
Compound: MaxCyte STX® and MaxCyte VLX® Large Scale Transfection System
Company: MaxCyte (USA - MD) Cold Spring Biotech (Taiwan)
Therapeutic area: Technology - Services
Type agreement: distribution
Action mechanism: MaxCyte STX® Scalable Transfection System and MaxCyte VLX® Large Scale Transfection System are tools for use in drug discovery research and screening and protein production environments. These products provide for the rapid development and consistent production of billions of (co)transfected primary cells, stem cells, and cell lines for protein and antibody production, for rapid response vaccine development, and for cell-based assays with comparable results and Seamless Scalability™ from the bench to HTS and pilot and production scale.
Disease:
Details: * On April, 27, 2015, MaxCyte®, a pioneer in scalable, high-performance cell transfection systems, announces the appointment of Cold Spring Biotech Corp. as the exclusive authorized distributor of the MaxCyte STX® Scalable Transfection System and the MaxCyte VLX® Large Scale Transfection System in China, Taiwan, and Hong Kong. With offices in Beijing, Shanghai, Guangzhou, and other cities in China, Cold Spring Biotech Corp. distributes instruments, reagents, and consumables for some the biggest manufacturers in the biotechnology market. In addition to its distribution services, CSB provide R&D consultation services on research projects and experimental techniques.
Financial terms:
Latest news:
